IntegenX Is Awarded Patent From The United States Patent And Trademark Office (USPTO)

PLEASANTON, Calif.--(BUSINESS WIRE)--IntegenX announced today that it has been awarded United States Patent 9,012,236, entitled “Universal Sample Preparation System” by the USPTO. The patented invention relates broadly to microfluidic methods. In particular, the invention focuses on moving reagents, such as PCR reagents, from a sealed storage chamber into a microfluidic system. This is the 17^th U.S. patent issued to IntegenX, whose patent estate includes 35 issued and owned U.S. patents, 11 pending U.S. patent applications and 13 patents and applications in international markets.

“As the market leader in Rapid DNA testing, it is important to invest in protecting our key technologies”

“As the market leader in Rapid DNA testing, it is important to invest in protecting our key technologies,” says Robert A. Schueren, President and CEO of IntegenX. “This patent further demonstrates our broad range of capabilities in developing novel sample to answer systems.”

IntegenX Inc., headquartered in Pleasanton, California, is the market leader of Rapid Human DNA identification technology. IntegenX technology platforms integrate advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing for forensics and law enforcement applications. For more information, please visit www.integenx.com. IntegenX, the IntegenX logo, and RapidHIT are the registered trademarks of IntegenX Inc.

Help employers find you! Check out all the jobs and post your resume.